DUSA PHARMACEUTICALS, INC. NASDAQ: DUSA

WILMINGTON, MASSACHUSETTS--(Marketwire - Nov. 4, 2008) - DUSA Pharmaceuticals, Inc.^® (NASDAQ GM:DUSA), a dermatology company that is developing and marketing Levulan^® photodynamic therapy (PDT) and other products targeting patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 11:10 a.m. ET at The New York Palace Hotel in New York. Interested investors can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website for 14 days following the presentation.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan^® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 or 2 actinic keratoses of the face or scalp. DUSA's other dermatology product is ClindaReach^TM. DUSA is also researching additional indications for Levulan PDT including oral leukoplakia in collaboration with National Institute of Health (NIH) and the prevention of AKs and SCCs. DUSA is based in Wilmington, Mass. Please visit the company's website at www.dusapharma.com for more information.